医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Integra Holdings Closes $3 Million Investment from Guangxi Wuzhou Pharmaceutical Group

2014年12月08日 PM09:30
このエントリーをはてなブックマークに追加


 

JERUSALEM

Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem, announced today that it has received US $3 million investment from Guangxi Wuzhou Pharmaceutical Group Co., Ltd., a subsidiary of the Guangxi Wuzhou Zongheng Group, a Chinese investment holdings company. The funds raised will be used to advance Integra Holdings’ existing portfolio companies and to create new companies, based on promising projects originating from the Hebrew University.

Integra Holdings, founded by Yissum in 2012, has a robust portfolio of companies operating in a variety of therapeutic areas such as oncology, Alzheimer’s disease, infectious diseases, analgesia and inflammation. The innovative products developed by the portfolio companies range in maturity from pre-clinical stages of development, through clinical stages, to registration. Currently, the portfolio includes Ayana, Atox Bio, Avraham Pharmaceuticals, Lipomedix, Tiltan Pharma, Lipocure and HIL Applied Medical, in addition to two new companies, which are now being established and develop products with expected short time to market. Investors in Integra Holdings are Invatech Holdings, a group of private US and Israeli investors; Halman-Aldubi Provident and Pension Fund; the Funds of Teaching Personnel and the HUJI Provident Fund. Integra Holdings has raised a total of US $12 million to date.

“We are pleased to have Guangxi Wuzhou Pharmaceutical Group join as an investor that can also assist us in introducing biotech products and technologies based on research performed at the Hebrew University to the Chinese market,” stated Yaacov Michlin, CEO of Yissum and Chairman of Integra Holdings’ Board of Directors. “After only two years since its inception, Integra Holdings has obtained an investment at twice its original valuation.”

“We welcome Guangxi Wuzhou Pharmaceutical Group’s investment and vote of confidence in the therapeutic products of our exclusive companies and our unique model of advancing cutting edge science and innovation towards commercial realization,” commented Dr. Liana Patt, CEO of Integra Holdings. “We look forward to using this investment to advance products currently in the pipeline of our portfolio companies, and forming new companies based on the Hebrew University’s most promising inventions in the field of life science.”

This transaction was made possible through the local Chinese contacts of the Lakers Holdings Group.

About Guangxi Wuzhou Pharmaceutical Group

Guangxi Wuzhou Pharmaceutical Group Co., Ltd. is a wholly owned subsidiary of the Guangxi Wuzhou Zongheng Group, a Chinese investment holdings company traded on the Shanghai Stock Exchange (SHA:600252) with a current market cap of approximately US $2.8B. The parent company focuses on pharmaceuticals, health and food products, while Guangxi Wuzhou Pharmaceutical Group is the largest pharmaceutical company in Guangxi, and among the 20 largest pharmaceutical companies in China.

About Integra Holdings

Founded by Yissum, Integra Holdings is a unique venture fund, focusing on an exclusive selection of biotech companies with proprietary solutions and a competitive advantage in their respective fields. Integra Holdings takes a hands-on approach by providing its portfolio companies with the strategic planning, business development and R&D guidance they need to bring their technology to the market. For more information, please visit www.integra-holdings.com.

CONTACT

Yissum Ltd.
Tsipi Haitovsky
Global Media Liaison
+972-52-598-9892
tsipih@yissum.co.il

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Delos™(中国)宣布健康材料与健康产品数据库首期启动
  • Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains
  • CANbridge Pharmaceutical and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics
  • 武田呈报3期ALTA-1L试验结果,显示在晚期ALK+非小细胞肺癌一线治疗中,ALUNBRIG® (brigatinib)的颅内有效性优于克唑替尼
  • Philip Morris International Launches Next Generation of IQOS, the World’s Leading Heated Tobacco Product